Key result
Diabetic patients had a significantly higher 2-year rate of major adverse cardiac events after acute myocardial infarction stabilization compared to nondiabetic patients (8.0% vs 3.7%; P<0.01).
Why the study?
Does diabetes mellitus increase the risk of MACE in stabilized patients after acute myocardial infarction?
Cohort (n=2,176)
Does diabetes mellitus increase the risk of MACE in stabilized patients after acute myocardial infarction?
Absolute Event Rate: 8% vs 3.7%
p-value: p=<0.01
Even after 1-month stabilization post-AMI, diabetic patients have a significantly higher 2-year risk of MACE compared to matched nondiabetic patients, highlighting the need for intensive secondary prevention.
Elevated MACE risk in diabetics post-AMI stabilization warrants clinical attention; leaves open whether targeted interventions improve outcomes.
This study assessed the 2-year clinical outcomes of patients with diabetes mellitus (DM) after acute myocardial infarction (AMI) in a cohort of the DIAMOND (DIabetic Acute Myocardial infarctiON Disease) registry. Clinical outcomes were compared between 1088 diabetic AMI patients in the DIAMOND registry after stabilization of MI and 1088 nondiabetic AMI patients from the KORMI (Korean AMI) registry after 1 : 1 propensity score matching using traditional cardiovascular risk factors. Stabilized patients were defined as patients who did not have any clinical events within 1 month after AMI. Primary outcomes were the 2-year rate of major adverse cardiac events (MACEs), a composite of all-cause death, recurrent MI (re-MI), and target vessel revascularization (TVR). Matched comparisons revealed that diabetic patients exhibited significantly lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate and smaller stent size. Diabetic patients exhibited significantly higher 2-year rates of MACE (8.0% vs 3.7%), all-cause death (3.9% vs 1.4%), re-MI (2.8% vs 1.2%), and TVR (3.5% vs 1.3%) than nondiabetic patients (all P < 0.01), and higher cumulative rates in Kaplan-Meier analyses of MACE, all-cause death, and TVR (all P < 0.05). A multivariate Cox regression analysis revealed that chronic kidney disease, LVEF < 35%, and long stent were independent predictors of MACE, and large stent diameter and the use of drug-eluting stents were protective factors against MACE. The 2-year MACE rate beyond 1 month after AMI was significantly higher in DM patients than non-DM patients, and this rate was associated with higher comorbidities, coronary lesions, and procedural characteristics in DM.
No takes yet. Share an insight, caveat, or question.
Hur et al. (2016) conducted a cohort in Acute myocardial infarction (n=2,176). Diabetes mellitus vs. Nondiabetic patients was evaluated on 2-year rate of major adverse cardiac events (MACEs), a composite of all-cause death, recurrent MI, and target vessel revascularization (p=<0.01). Diabetic patients had a significantly higher 2-year rate of major adverse cardiac events after acute myocardial infarction stabilization compared to nondiabetic patients (8.0% vs 3.7%; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: